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16RESEARCH Open AccessAssessment of endothelium and inflammatory
response at the onset of reperfusion injury in
hand surgery
Pranitha Kamat1, Bettina Juon2, Brigitte Jossen1, Thusitha Gajanayake2, Robert Rieben1,2* and Esther Vögelin2Abstract
Background: Activation of the endothelium, complement activation and generation of cytokines are known events
during ischemia-reperfusion (I/R) that mediate tissue injury. Our aim was to elucidate their respective participation
at the onset of the reperfusion phase. Tourniquet application in hand surgery causes short-term ischemia, followed
by reperfusion and was therefore used as the model in this study.
Methods: Ten patients were included in the study after obtaining informed consent. A tourniquet was placed on
the upper arm and inflated to 250 mmHg for 116 ± 16 min, during which the surgery was performed. Venous
blood and tissue samples from the surgical area were taken at baseline as well as 0, 2, and 10 min after reperfusion
and analyzed for the following parameters: Endothelial integrity and/or activation were analyzed by measuring
heparan sulfate and syndecan-1 in serum, and vWF, heparan sulfate proteoglycan as well as CD31on tissue.
Complement activation was determined by C3a and C4d levels in plasma, levels of C1-inhibitor in serum, and IgG,
IgM, C3b/c, and C4b/c deposition on tissue. Cytokines and growth factors IL-5, IL-6, IL-7, IL-8, IL-10, IL-17, G-CSF,
GM-CSF, MCP-1, TNFα, VEGF, and PDGF bb were measured in the serum. Finally, CK-MM levels were determined in
plasma as a measure for muscle necrosis.
Results: Markers for endothelial activation and/or integrity as well as complement activation showed no significant
changes until 10 min reperfusion. Among the measured cytokines, IL-6, IL-7, IL-17, TNFα, GM-CSF, VEGF, and PDGF
bb were significantly increased at 10 min reperfusion with respect to baseline. CK-MM showed a rise from baseline
at the onset of reperfusion (p< 0.001) and dropped again at 2 min (p< 0.01) reperfusion, suggesting ischemic
muscle damage.
Conclusions: In this clinical model of I/R injury no damage to the endothelium, antibody deposition or
complement activation were observed during early reperfusion. However, an increase of pro-inflammatory cytokines
and growth factors was shown, suggesting a contribution of these molecules in the early stages of I/R injury.
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Ischemia / reperfusion (I/R) injury is a common source
of pathology in many vascular diseases. Mechanisms
underlying I/R injury have been studied extensively and
are known to engage a spectrum of pathways. Elucidat-
ing the key molecules involved in triggering the entire* Correspondence: robert.rieben@dkf.unibe.ch
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reproduction in any medium, provided the orprocess of injury is important to help develop targeted
therapy to attenuate I/R injury in its early stages.
In any vascularized organ or tissue, a monolayer of
endothelial cells (EC) forms the interface between blood
and the surrounding tissue. Among other factors, the
glycocalyx covering the endothelium, plays a critical role
in maintaining the homeostasis of the blood vessel wall
[1]. The conditions during I/R cause this glycocalyx layer
to partly shed [2], which occurs already during ischemia
and more significantly during reperfusion [3]. Glycocalyx
shedding activates the endothelium by transforming it
into a pro-inflammatory and pro-coagulant phenotypeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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acts as an interface between blood and tissue, forms
receptors for many inflammatory molecules including
cytokines and therefore participates in inflammation
[5,6]. Shedding of the glycocalyx after 2 min of reperfu-
sion has been shown in humans [7], but the respective
study was based on a setting of cardiopulmonary bypass
and data on I/R induced shedding of the glycocalyx in
smaller, peripheral blood vessels are lacking.
Complement activation leads directly to tissue necrosis
and trafficking of immune cells. Various knockout ani-
mal models have illustrated the participation of natural
antibodies and complement in propagation of I/R injury
[8,9]. The importance of complement in I/R injury has
been reviewed [10]. Complement thus has the potential
to significantly contribute to early reperfusion injury.
The model used in this study was that of tourniquet-
induced I/R injury. Tourniquet application in extremity
surgery is a prerequisite to provide a blood-less environ-
ment during surgery. The blood flow in the ischemic
limb is restored after surgery by releasing the tourniquet.
Use of the tourniquet thereby comes with the risk of I/R
injury. Clinically, this manifests as pain, swelling, pro-
longed hypoesthesia of peripheral nerves, tissue necrosis
along with systemic effects, which the surgeons try to
avoid by limiting tourniquet times to a maximum of 2
hours [11-15]. Several studies in humans have been
dedicated to understanding I/R injury due to tourniquet
application in upper and lower limbs. These studies have
shown the involvement of radical oxygen species (ROS)
[16], expression of adhesion molecules [17], recruitment
of activated leukocytes [18] and thereby progression of
inflammation. The process of I/R injury in skeletal
muscle has been extensively studied [19] and reviewed
[20]. However, the role of cytokines during early reperfu-
sion is still unclear and yet to be investigated in upper
limb I/R injury. This would be important, as cytokines
apart from trafficking immune cells are known to cause
shedding of the endothelial glycocalyx [21].
Based on the above-cited literature, including our own
studies, we hypothesized that the endothelium together
with the innate immune response including natural anti-
bodies, complement, cytokines and growth factors,
would be involved in the very early reperfusion phase.
The aim of this study was to assess the involvement and
relative contribution of these different factors in the ini-
tial phase of reperfusion injury.
Methods
Ten patients undergoing elective hand surgery under
tourniquet application were included in the study upon
approval by the ethical committee of the Canton of
Bern, Switzerland (reference number 033/09). Informed
consent from the patients was obtained prior to thestudy. Exclusion criteria were trauma, anticoagulation,
rheumatoid disease, age under sixteen years and dia-
betes. Patient details with their age, gender, main disease
for operation, anatomical location of the operation, dis-
orders, drugs given, tourniquet time, etc. are given in
Table 1.
The tourniquet device was the A.T.S. 2000 automatic
Tourniquet System (Zimmer, Inc. Warsaw, IL, USA)
with a low profile cuff and accurate pressure monitoring.
Before the cuff was applied on the upper arm a cuff
sleeve to reduce shearing of soft tissue was used. After
standardized disinfection with 0.5% chlorhexidin and
sterile dressing surgery, samples were collected for the
study.Sample collection
Venous blood leaving the surgical area was collected
from the cubital vein, distal to the tourniquet, with a
sterile syringe. Collected blood was immediately trans-
ferred into S-monovette tubes (Sarstedt AG, Nümbrecht,
Germany) containing EDTA (1.6 mg/ml) to obtain
EDTA-plasma, and to tubes containing a clotting activa-
tor (glass pearls) to obtain serum. Samples were col-
lected before application of tourniquet (baseline), and
immediately after release of the tourniquet (at 0, 2 and
10 min after reperfusion). Samples were kept on ice until
centrifugation at 3000 rpm for 10 min. Serum and
EDTA-plasma were stored in aliquots at −80°C until use.
Subcutaneous tissue samples containing blood vessels
were taken from the surgical area distal to the tourni-
quet, and therefore within the ischemic area. Sampling
was done immediately after the application of tourniquet
(baseline), just before releasing the tourniquet (end is-
chemia) and 10 minutes after release of tourniquet
(10 min reperfusion). Biopsies were fixed in 2% formal-
dehyde for 24 hours and then transferred into 18% su-
crose for 15 hours. They were embedded in Shandon
M1 embedding matrix (Thermo Scientific, Inc., Geneva,
Switzerland) and stored at -20°C until sectioned.Markers for EC integrity/activation and detection of
complement activation on tissue
Free float technique was used for immunostaining of tis-
sue samples. In brief, 30 μm thick cryosections were cut
from each sample and treated with TBS-Triton X100 for
15 min. EC integrity/activation were assessed by mouse
anti-human heparan sulfate proteoglycan (HSPG; Abcam
plc., Cambridge, UK), mouse anti-human von Willebrand
factor (vWF; DAKO, Glostrup, Denmark), mouse anti-
human CD31 (eBioscience, Inc., San Diego, CA, USA).
As secondary antibodies we used Dylight 488 labeled
donkey anti-mouse (Jackson ImmunoResearch Labora-
tories, Inc., West Grove, PA, USA), Cy3-labeled donkey
Table 1 Patient details
No. Age/
Gender
Main disease
for operation
Location
of
operation
Cardiovascular
disorder
Other
disorders
Angiological
disorder
Smoker Drugs (/day) Statins
or
Aspirin
Tourniquet
time (min)
1 35/ M Tendon
adhesions
after complex
reconstruction
of left hand
Dorsal
hand
No Mild hepatitis No No No No 124
2 43/ F Flexor tendon
rupture left
hand
Volar
hand
No No No No No No 112
3 33/ F Tendon
adhesions
after complex
reconstruction
of right hand
Dorsal
hand
No No No No No No 118
4 29/ M Ulnar nerve
compression left
elbow
Elbow No No No No No No 78
5 48/ M Ulnar nerve
compression left
elbow
Elbow No No No Yes No No 105
6 60/ F Rhizarthrosis
right hand
Dorsal
hand
No No No Yes Pantoprozole No 128
7 47/ M Posttraumatic
arthritis of distal
radio ulnar
joint of left
hand
Dorsal
hand
Hypertension Epilepsy No No Lamotrigine,
Amitriptyline
Sodium valproate,
Carvedilol,
Chlorthalidone,
Captopril /
Hydrochlorothiazide
No 117
8 62/ F Rhizarthrosis right
hand
Dorsal
hand
No No No No No No 132
9 37/ M Scaphoid non
union right
hand
Volar
hand
No No No No No No 127
10 68/ F Rhizarthrosis
right hand
Dorsal
hand
Hypertension,
16 years prior
PTCA and stent
Hypothyroidism No No Atenolol,
Ranitidine,
Levothyroxine
(0.1 mg),
Estradiol (1 mg)
Aspirin 122
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rabbit anti-mouse (DAKO).
The following antibodies were used to determine natural
antibody binding and complement activation: Cy3 labeled
goat anti-human IgG (KPL, Inc., Gaithersburg, MD, USA),
allophycocyanin labeled goat anti-human IgM (Open
Biosystems / Thermo Scientific), FITC labeled rabbit anti-
human C3b/c (DAKO), and FITC-labeled rabbit anti-
human C4b/c (DAKO).
Scoring of stained tissue sections
The sections had highly heterogeneous vessel sizes ap-
proximately ranging between 12 – 100 μm. The vari-
ation due to vessel size and inter-batch differences
during the staining procedure were overcome by the fol-
lowing scoring protocol: Sections of skeletal muscle from
the hand of a healthy human were used as common con-
trol in every staining batch. Images of a representative
blood vessel were taken under the confocal microscope
from all sections including the common control. With
Imaris software (Bitplane AG, Zurich, Switzerland), the
area of the vessel was calculated from the image, and a
histogram of the color channel of interest for the same
area was obtained. The histogram of the common con-
trol was used to normalize histograms of other tissues
from the same batch. This enabled sections from differ-
ent batches to be comparable. Area under the curve
(AUC) values were obtained from the normalized histo-
gram for each tissue and divided by the area of the vessel
to obtain a final score for the section. Sections were then
compared with their final scores, which considered the
size of the vessel and the intensity of staining within that
vessel. Sections were blinded at all times for the analysis.
Analysis of EC integrity/activation and complement
activation in venous blood
ELISA kits were used to determine the concentrations of
heparan sulfate (HS) and syndecan-1 as markers of EC
activation. Kits for C3a, C4d and functional C1-inhibitor
were used to analyze complement activation. Assays
were performed according to manufacturers' protocols
and concentrations were determined by comparing with
standards provided with the kit. HS (Seikagaku Corp.,
Tokyo, Japan) and syndecan-1 (Diaclone, Gene-Probe
Inc., San Diego, CA, USA) were measured in blood
serum samples. C3a and C4d (Quidel Corp., San Diego,
CA, USA) were measured in EDTA plasma samples and
functional C1-inhibitor (Quidel Corp., San Diego, CA,
USA) measured in blood serum.
Analysis of cytokines in circulation
A multiplex immunoassay, consisting of fluorescent
microspheres conjugated with a monoclonal antibody
specific for a target protein, was used to detect an arrayof cytokines. Kits for IL-5, IL-6, IL-7, IL-8, IL-10, IL-17,
G-CSF, GM-CSF, MCP-1, TNFα, VEGF, and PDGF bb
were purchased from Bio-Rad (Bio-Rad Laboratories,
Inc., Hercules, CA, USA) and multiplex analysis was
performed on a Bio-Plex 100 system (Bio-Rad). Assays
were performed according to manufacturer’s instruc-
tions. Briefly, plasma was diluted 1:2 and incubated with
antibody-coupled beads. Complexes were washed and
then incubated with biotinylated detection antibody fol-
lowed by streptavidin-phycoerythrin prior to assessing
titers of cytokine concentration. Recombinant cytokines
were used to establish standard curves. Analyte concen-
trations were calculated using the Bio-Plex Manager 4.0
Software (Bio-Rad).
Measurement of skeletal muscle injury
An ELISA kit for measuring skeletal muscle creatine
kinase (CK-MM, from USCN Life Sciences, Wuhan,
China) was used to measure skeletal muscle injury. The
assay was performed according to the manufacturers'
protocol and samples were analyzed in duplicates for
each time point. Concentrations were determined by
comparing with standards provided with the kit.
Statistical analysis
All data was initially checked for normality by Kolmo-
gorov-Smirnov test. Time dependant changes were
tested by Repeated Measures ANOVA test with confi-
dence interval set to 95%. Bonferroni's multiple com-
parison test was used as a post test. When only two time
points had to be statistically compared, two tailed paired
t-test was used with the level of significance set to 95%.
All statistics calculations were done in Prism 4.0a for
Macintosh (GraphPad Software, Inc., La Jolla, CA,
USA).
Results
The average tourniquet time for the 10 patients was 116
± 16 minutes.
Shedding of glycocalyx and EC integrity/activation
Heparan sulfate and syndecan-1 were measured by
ELISA. Figure 1 shows each patient as an individual dot
and the mean values are represented with a dash. Given
below in brackets are the mean and standard deviation
values for the ten patients at every time point. Statis-
tical analysis showed no time dependent change in
levels of HS at baseline (6.5 ± 1.9 μg/ml), 0 min reper-
fusion (5.6 ± 1.9 μg/ml), 2 min reperfusion (5.5 ±
2.1 μg/ml) and 10 min reperfusion (6.2 ± 1.8 μg/ml).
Similarly, syndecan-1 levels showed no time dependent
changes from baseline (196.4 ± 28.4 ng/ml) to 0 min
reperfusion (196.5 ± 35.8 ng/ml), 2 min reperfusion
Figure 1 Serum levels of Heparan sulfate and Syndecan-1 . Serum levels of HS and syndecan-1 were measured by ELISA. Samples from
baseline were compared with 0, 2, and 10 min reperfusion. No significant changes between time points were found by Repeated Measures
ANOVA, n = 10.
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27.5 ng/ml).
The endothelial lining of blood vessels was studied by
immunostaining the tissue sections for HSPG, vWF and
CD31 as markers of EC integrity/activation. Table 2
shows mean values ± standard deviations for each mar-
ker at the different time points. Statistics showed no sig-
nificant differences in staining intensity, confirming no
loss of endothelial integrity or activation of the EC until
10 min reperfusion. Representative pictures for HSPG at
the different time points are shown in Figure 2.
Binding of antibodies and activation of complement
system
Products of complement activation were measured by
ELISA at baseline and after 10 min of reperfusion in
EDTA plasma samples. Figure 3 shows each patient as
an individual dot and the mean represented with a
dash. Given below in brackets are the mean andTable 2 Immunofluorescence staining for markers of EC integ
Markers of EC integrity / activation Baseline
HSPG 0.45 ± 0.16*
vWF 0.34 ± 0.37
CD31 2.20 ± 3.99
*Values are mean ± standard deviation of immunofluorescence scores (quantitationstandard deviation value of the ten patients at every
time point. The paired t-test showed no significant dif-
ferences between the levels of C3a at baseline (247.0 ±
221.5 ng/ml) and at 10 min reperfusion (144.7 ± 161.1
ng/ml) and of C4d at baseline (42.5 ± 35.9 ng/ml) and
10 min reperfusion (67.6 ± 78.4 ng/ml). The levels of
functional C1-inhibitor were expressed as percentage of
normal levels in human blood and measured at baseline
(93.2 ± 8.2%), 0 min reperfusion (90.2 ± 8.7%), 2 min
reperfusion (95.5 ± 4.8), and 10 min reperfusion (94.2 ±
7.4). In line with the C3a and C4d results, also no sig-
nificant differences were found for the levels of C1-
inhibitor (Figure 4).
In the tissue samples, deposition of IgM, IgG, C3b/c
and C4b/c were analyzed by immunostaining. Table 3
shows mean values ± standard deviations for each anti-
gen at the different time points. Statistical analysis
revealed no significant differences for antibody- or com-
plement deposition in tissue between baseline andrity / activation
End ischemia 10 min reperfusion P value
0.44 ± 0.14 0.58 ± 0.11 n.s.
0.64 ± 0.64 0.60 ± 0.49 n.s.
0.61 ± 0.83 0.51 ± 0.57 n.s.
by Imaris software), n = 10.
Figure 2 Immunofluorescence staining for HSPG. Tissue samples from baseline, end ischemia and 10 min reperfusion were analyzed by
Immunofluorescence for HSPG. Pictures are representative for the shown time points. No statistical differences in HSPG expression were found by
Repeated Measures ANOVA, n = 10. Green =HSPG, blue =DAPI staining of nuclei. Scale bars = 150 μm.
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and C4b/c deposition are shown in Figure 5.Cytokine levels
An array of cytokines and growth factors, namely IL-5,
IL-6, IL-7, IL-8, IL10, IL17, G-CSF, GM-CSF MCP-1,
TNFα, VEGF and PDGF bb, were measured by Bio-Plex
assay. Because several of the measurements revealed low
values outside of the range of the standard curves, raw
fluorescence intensity values were used for statistical
analysis, rather than the calculated concentrations of the
respective cytokines. Figure 6 shows each patient as an
individual dot with the mean represented by a dash. The
10 min reperfusion samples were significantly higher
than baseline for IL-6 (p = 0.024), IL-7 (p = 0.006), IL-17
(p = 0.034), GM-CSF (p = 0.017), TNFα (p = 0.046), VEGF
(p = 0.007), and PDGF bb (p = 0.0001) as analyzed by
paired t-test.Skeletal muscle injury
Creatine kinase-MM was measured in plasma samples
as a marker for skeletal muscle injury. Figure 7 shows
each patient as an individual dot and the mean repre-
sented by a dash at every time point. The values given
below are mean ± standard deviation. CK-MM valuesFigure 3 Plasma levels of C3a and C4d. Plasma levels of the complemen
baseline and after 10 min reperfusion were not statistically different as shoincreased significantly from 2066 ± 1122 U/L at baseline
to 5908 ± 1843 U/L at 0 min reperfusion (p< 0.001). At
2 min reperfusion the levels significantly dropped from
0 min reperfusion to 3504 ± 1855 U/L (p< 0.001). How-
ever, at 10 min reperfusion, CK-MM levels (4296 ± 1894
U/L) were still higher than at baseline (p< 0.01).Discussion
As an interface between the circulating blood and tissue
it is not difficult to consider the EC to react immediately
to pathophysiological processes during I/R. An import-
ant reaction of the endothelium is the shedding of its
native, anticoagulant and anti-inflammatory surface
layer, the glycocalyx [22]. The latter is composed mainly
of heparan sulfate proteoglycans, among which synde-
cans as core proteins [7]. We therefore measured the
levels of shed heparan sulfate, syndecan-1 in serum and
expression of HSPG on tissue, which showed no changes
from baseline to 10 min reperfusion. Together, these
data support the notion that no significant activation of
EC occurred in our setting of tourniquet-induced ische-
mia and reperfusion. This finding is in contrast to earlier
reports, for example on patients undergoing coronary
artery bypass grafting under extracorporeal circulation,
where increased serum levels of syndecan-1 and HSt activation markers C3a and C4d were measured by ELISA. Values at
wn by Paired t-Test, n = 10.
Figure 4 C1-Inhibitor in serum. Functional C1-inhibitor levels in serum were measured by ELISA. Values were not significantly different between
time points as shown by Repeated Measures ANOVA.
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the latter study, however, the tubings and filters in the
extracorporeal circulation circuit, which are known to
lead to complement activation, may account for at least
part of the observed EC activation.
Other markers of EC activation documented previ-
ously are CD31 and vWF [23,24], and we included de-
tection of these antigens on tissue biopsies by
immunostaining. Earlier studies by Huhges et al. [25,26],
showed no significant increase in vWF plasma levels
after 10 min and 30 min of ischemia and 15 min and
30 min reperfusion, respectively. Our study confirms this
finding with no significant changes in vWF and CD31
expression in biopsies, which further indicate minimal
EC activation or damage during early reperfusion. How-
ever, the study does not consider differences in the con-
stitutive expression patterns of these antigens, which
could vary due to heterogeneity in vessel size as shown
for vWF [27].
Previous studies on murine skeletal muscle I/R injury
models have identified natural IgM antibodies as a major
initiator of the activation of the complement system,
which was also shown to be causally related to the
observed tissue injury [8]. We therefore analyzed depos-
ition of IgM as well as IgG in the tissue. However, no
significant differences between ischemia and reperfusion
samples were found for these antibody isotypes. In line
with the absence of antibody deposition, markers for
complement activation C3b/c, C4b/c on tissue and C3a,
C4d in plasma did not change until 10 min reperfusion.Table 3 Immunofluorescence staining for markers of complem
Antibody and complement deposition in tissue Baseline
IgG 1.03 ± 9.60*
IgM 0.02 ± 0.02
C3b/c 0.12 ± 0.13
C4b/c 0.16 ± 0.10
*Values are mean ± standard deviation of immunofluorescence scores (quantitationThis suggests that no significant activation of the com-
plement system occurred in our setting of tourniquet-
induced ischemia and reperfusion injury. Also the levels
of functional C1-inhibitor, which is the only known
physiologic inhibitor of classical complement pathway
activation [28], showed no changes from baseline to
10 min reperfusion.
Pro-inflammatory cytokines are secreted to preserve
immune integrity and stimulate repair mechanisms to
counteract the ongoing tissue damage [29,30]. The pro-
inflammatory cytokines IL-1 and TNFα in particular are
released by monocytes and macrophages during the
acute phase of I/R injury and in turn stimulate the pro-
duction of IL-6 [31]. In our study we found that TNFα
and IL-6 were significantly elevated in serum at 10 min
reperfusion as compared to baseline. This result is in
line with two reports of tourniquet application in lower
limb surgery, where a rise in IL-6 was shown at 2 h and
4 h reperfusion, respectively, in the draining blood of the
ischemic limbs [19,32]. We also found a significant rise
in the levels of IL-17 from baseline, highlighting the in-
volvement of another pro-inflammatory molecule, which
is known to induce EC to secrete cytokines.
Among the cytokines secreted by EC, IL-7 showed a
significant rise in the 10 minutes reperfusion sample,
but this was not the case for IL-8. Predominantly anti-
inflammatory cytokines like IL-10 and IL-5 did not show
any significant changes at 10 min reperfusion.
To our knowledge, the role of MCP-1 has not yet been
studied in human skeletal muscle I/R injury. Studies onent activation
End ischemia 10 min reperfusion P value
0.81 ± 0.60 0.50 ± 0.40 n.s.
0.06 ± 0.08 0.03 ± 0.03 n.s.
0.12 ± 0.22 0.13 ± 0.22 n.s.
0.29 ± 0.46 0.22 ± 0.31 n.s.
by Imaris software), n = 10.
Figure 5 Immunofluorescence staining for C3b/c and C4b/c. Tissue samples from baseline, end ischemia and 10 min reperfusion were
analyzed by Immunofluorescence for deposition of the complement components C3b/c and C4b/c. Pictures are representative for the time
points and no significant differences were found by Repeated Measures ANOVA, n = 10. Green =C3b/c / C4b/c, blue =DAPI staining of nuclei.
Scale bars = 50 μm.
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inflammation [33] and muscle regeneration [34]. Our data
show no significant changes in the levels of MCP-1 until
10 min of reperfusion. On the other hand, an increased
level of GM-CSF, but not of G-CSF, was found, probably
due to the recruitment of monocytes at the site of ischemia.
VEGF [35] and PDGF bb [36] are growth factors that
help in angiogenesis and formation of new blood vessels
and are induced as a response to ischemia. In the
present study we could also show this type of vascular
responses to ischemia by significantly higher plasma
levels of VEGF and PDGF bb at 10 min reperfusion.
Finally, CK-MM was measured as a marker for skeletal
muscle injury [37]. The observed significant rise of the
enzyme levels at end of ischemia (0 min reperfusion) as
well as at 10 min reperfusion when compared to baseline
indicates that a certain level of skeletal muscle injury is
occurring in our model, despite the apparent absence of
activation of complement and EC.Clinical significance of the study
As mentioned previously the use of tourniquet on a limb
renders it to the risk of I/R injury which clinically mani-
fests as pain, swelling, prolonged hypoesthesia of periph-
eral nerves, tissue necrosis along with systemic effects.
For the formation of edema, which may lead to thefeared compartment syndrome, EC activation and dam-
age are key events. Their absence during the very early
reperfusion phase (as shown in our study) may offer a
window of opportunity to protect the endothelium and
thus to prevent further reperfusion injury, for example
by local use of endothelial cell protective substances
which proved to be effective to prevent I/R injury in ex-
perimental myocardial infarction [38,39].Conclusions and limitations
The aim of this study was to assess the endothelium and
the inflammatory response during the early phase of
reperfusion. In this clinical model of tourniquet induced
I/R injury, we show an active involvement of the inflam-
matory cascade with a rise in cytokines, mainly TNFα,
IL-6, IL-17, IL-7, GM-CSF, PDGF bb and VEGF, during
early reperfusion. Additionally a rise in CK-MM was
observed indicating a certain degree of skeletal muscle
injury post surgery. However, in contrast to our original
hypothesis, no significant activation of EC or the comple-
ment system could be observed until 10 min reperfusion.
A limitation of the study is that we cannot account for
the source of the increased cytokine production as
observed, which could be local or systemic. Additional
analysis of the same parameters in samples taken from
the systemic circulation would have been helpful. The
Figure 6 Measurement of cytokines and growth factors in serum. The cytokines IL-5, IL-6, IL-7, IL-8, IL-10, IL-17, G-CSF, GM-CSF MCP-1, TNFα,
VEGF and PDGF bb were measured by Bio-Plex assay. Baseline samples were compared with 10 min reperfusion samples for each cytokine.
*p< 0.05, **p< 0.005, ***p< 0.0005 (two-tailed Student's t-test), n = 10.
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phase is a limitation of the study. Clinically, edema
becomes apparent only several hours after surgery and
additional studies with analyses of plasma samples after
reperfusion times of 6 h or more need to be done. An-
other limitation of the study is the ischemia period withFigure 7 Plasma levels of creatine kinase MM. CK-MM was measured b
(0 min reperfusion) as compared to baseline. Levels dropped again during
reperfusion (as shown by Bonferroni’s post test for Repeated Measures ANOa rather wide standard deviation and the varying clinical
background and underlying diseases of the patients.
However, there is no scope for standardization of these
two parameters in a clinical setting like the current
study, and more uniform experiments in this direction
will have to be conducted in animal models.y ELISA and found to be significantly higher at the end of ischemia
the reperfusion phase, but were still higher than baseline after 10 min
VA), n = 10.
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